Energex System's Experimental Non-Pharmicalogical Treatment Promising in Reducing Viral Load in Hepatitis C Patients

[Guest guest]

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=6500010

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

11/22/04 -- Energex Systems, Inc. announced today that preliminary results

of its Hepatitis C clinical trial have shown consistent and drastic

reductions in viral load in trial participants treated with its

Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food

and Drug Administration (FDA) in October, 2004.

Hepatitis C is a viral infection of the liver and a major cause of acute

hepatitis and chronic liver disease, including cirrhosis and liver cancer,

and is now recognized as the leading cause of liver transplantation in the

United States. HCV is spread primarily by direct contact with human blood.

The World Health Organization estimates that about 170 million people are

infected with HCV, about 3% of the world's population. Approximately 5

million Americans are infected with HCV, and there are 8,000-10,000 such

deaths each year in the United States.

Energex's experimental treatment involves exposing a very small amount of an

infected subjects blood (3-4%) to a very precise amount of ultra-violet

light in the C band (UVC), for a very precise amount of time, explained

Petrie, the developer of the technology and Director of Engineering

at Energex Systems. " During treatment, a percentage of any pathogen in the

blood that is exposed to the UVC energy is inactivated. After exposure, the

blood carrying the inactive pathogen is returned to the patient through the

same portal it was drawn from. The result, we believe, is a stimulation of

the immune system " , said Petrie. The process takes 20-30 minutes.

In the trial, non-responders to Interferon/Ribaviran are administered 3 PCR

tests before treatment, on days 1,8, and 15. The average of the tests is the

baseline that post-treatment tests are compared to. After the blood draw on

day 15, the 1st treatment is administered, followed by the 2nd treatment on

day 17. Prior to the 3rd treatment on day 20, the first post-treatment PCR

test is administered and the result is compared to the baseline. The 4th and

5th treatments are administered on days 25 and 30 respectively. On day 33

the 1st PCR test after the last treatment is administered and compared to

the baseline. Additional PCR tests are administered on days 57, 64 and 71

and the average of the tests is compared to the baseline. Preliminary

results at day 33, established viral load reductions of 56, 91 and 96

percent in the 1st three trial participants.

" When you consider that we are treating non-responders; the average viral

load reduction of the 1st three participants was in excess of 81% in just a

17-day period, and there have been no adverse events, I believe it goes a

long way in validating our belief that our Hemo-Modulator technology will

soon become the treatment of choice for Hepatitis C and other RNA type

viruses " said J. Fagan, President of Energex Systems. We are excited

about the potential that our technology has to manage this hard-to-treat

disease, to reduce the cost of care, and to provide a better quality of life

for the millions that suffer from it. We are committed to expending whatever

resources are necessary to see that this technology continues through the

research and approval processes, and that it is accepted by the medical

community as the treatment of choice for this potentially life threatening

disease " , said Fagan.

Energex Systems is dedicated to developing medical technologies and

therapies with an emphasis on the treatment of conditions unmet by present

day therapies and reducing the cost of care.

Source: Energex Systems, Inc.

[Guest guest]

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=6500010

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

11/22/04 -- Energex Systems, Inc. announced today that preliminary results

of its Hepatitis C clinical trial have shown consistent and drastic

reductions in viral load in trial participants treated with its

Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food

and Drug Administration (FDA) in October, 2004.

Hepatitis C is a viral infection of the liver and a major cause of acute

hepatitis and chronic liver disease, including cirrhosis and liver cancer,

and is now recognized as the leading cause of liver transplantation in the

United States. HCV is spread primarily by direct contact with human blood.

The World Health Organization estimates that about 170 million people are

infected with HCV, about 3% of the world's population. Approximately 5

million Americans are infected with HCV, and there are 8,000-10,000 such

deaths each year in the United States.

Energex's experimental treatment involves exposing a very small amount of an

infected subjects blood (3-4%) to a very precise amount of ultra-violet

light in the C band (UVC), for a very precise amount of time, explained

Petrie, the developer of the technology and Director of Engineering

at Energex Systems. " During treatment, a percentage of any pathogen in the

blood that is exposed to the UVC energy is inactivated. After exposure, the

blood carrying the inactive pathogen is returned to the patient through the

same portal it was drawn from. The result, we believe, is a stimulation of

the immune system " , said Petrie. The process takes 20-30 minutes.

In the trial, non-responders to Interferon/Ribaviran are administered 3 PCR

tests before treatment, on days 1,8, and 15. The average of the tests is the

baseline that post-treatment tests are compared to. After the blood draw on

day 15, the 1st treatment is administered, followed by the 2nd treatment on

day 17. Prior to the 3rd treatment on day 20, the first post-treatment PCR

test is administered and the result is compared to the baseline. The 4th and

5th treatments are administered on days 25 and 30 respectively. On day 33

the 1st PCR test after the last treatment is administered and compared to

the baseline. Additional PCR tests are administered on days 57, 64 and 71

and the average of the tests is compared to the baseline. Preliminary

results at day 33, established viral load reductions of 56, 91 and 96

percent in the 1st three trial participants.

" When you consider that we are treating non-responders; the average viral

load reduction of the 1st three participants was in excess of 81% in just a

17-day period, and there have been no adverse events, I believe it goes a

long way in validating our belief that our Hemo-Modulator technology will

soon become the treatment of choice for Hepatitis C and other RNA type

viruses " said J. Fagan, President of Energex Systems. We are excited

about the potential that our technology has to manage this hard-to-treat

disease, to reduce the cost of care, and to provide a better quality of life

for the millions that suffer from it. We are committed to expending whatever

resources are necessary to see that this technology continues through the

research and approval processes, and that it is accepted by the medical

community as the treatment of choice for this potentially life threatening

disease " , said Fagan.

Energex Systems is dedicated to developing medical technologies and

therapies with an emphasis on the treatment of conditions unmet by present

day therapies and reducing the cost of care.

Source: Energex Systems, Inc.

[Guest guest]

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=6500010

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

11/22/04 -- Energex Systems, Inc. announced today that preliminary results

of its Hepatitis C clinical trial have shown consistent and drastic

reductions in viral load in trial participants treated with its

Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food

and Drug Administration (FDA) in October, 2004.

Hepatitis C is a viral infection of the liver and a major cause of acute

hepatitis and chronic liver disease, including cirrhosis and liver cancer,

and is now recognized as the leading cause of liver transplantation in the

United States. HCV is spread primarily by direct contact with human blood.

The World Health Organization estimates that about 170 million people are

infected with HCV, about 3% of the world's population. Approximately 5

million Americans are infected with HCV, and there are 8,000-10,000 such

deaths each year in the United States.

Energex's experimental treatment involves exposing a very small amount of an

infected subjects blood (3-4%) to a very precise amount of ultra-violet

light in the C band (UVC), for a very precise amount of time, explained

Petrie, the developer of the technology and Director of Engineering

at Energex Systems. " During treatment, a percentage of any pathogen in the

blood that is exposed to the UVC energy is inactivated. After exposure, the

blood carrying the inactive pathogen is returned to the patient through the

same portal it was drawn from. The result, we believe, is a stimulation of

the immune system " , said Petrie. The process takes 20-30 minutes.

In the trial, non-responders to Interferon/Ribaviran are administered 3 PCR

tests before treatment, on days 1,8, and 15. The average of the tests is the

baseline that post-treatment tests are compared to. After the blood draw on

day 15, the 1st treatment is administered, followed by the 2nd treatment on

day 17. Prior to the 3rd treatment on day 20, the first post-treatment PCR

test is administered and the result is compared to the baseline. The 4th and

5th treatments are administered on days 25 and 30 respectively. On day 33

the 1st PCR test after the last treatment is administered and compared to

the baseline. Additional PCR tests are administered on days 57, 64 and 71

and the average of the tests is compared to the baseline. Preliminary

results at day 33, established viral load reductions of 56, 91 and 96

percent in the 1st three trial participants.

" When you consider that we are treating non-responders; the average viral

load reduction of the 1st three participants was in excess of 81% in just a

17-day period, and there have been no adverse events, I believe it goes a

long way in validating our belief that our Hemo-Modulator technology will

soon become the treatment of choice for Hepatitis C and other RNA type

viruses " said J. Fagan, President of Energex Systems. We are excited

about the potential that our technology has to manage this hard-to-treat

disease, to reduce the cost of care, and to provide a better quality of life

for the millions that suffer from it. We are committed to expending whatever

resources are necessary to see that this technology continues through the

research and approval processes, and that it is accepted by the medical

community as the treatment of choice for this potentially life threatening

disease " , said Fagan.

Energex Systems is dedicated to developing medical technologies and

therapies with an emphasis on the treatment of conditions unmet by present

day therapies and reducing the cost of care.

Source: Energex Systems, Inc.

[Guest guest]

http://www.bio.com/industryanalysis/industryanalysis_news.jhtml?cid=6500010

Energex System's Experimental Non-Pharmicalogical Treatment Promising in

Reducing Viral Load in Hepatitis C Patients

11/22/04 -- Energex Systems, Inc. announced today that preliminary results

of its Hepatitis C clinical trial have shown consistent and drastic

reductions in viral load in trial participants treated with its

Hemo-Modulator technology. The trial is being conducted under an

Investigational Device Exemption (IDE) that was granted by the Federal Food

and Drug Administration (FDA) in October, 2004.

Hepatitis C is a viral infection of the liver and a major cause of acute

hepatitis and chronic liver disease, including cirrhosis and liver cancer,

and is now recognized as the leading cause of liver transplantation in the

United States. HCV is spread primarily by direct contact with human blood.

The World Health Organization estimates that about 170 million people are

infected with HCV, about 3% of the world's population. Approximately 5

million Americans are infected with HCV, and there are 8,000-10,000 such

deaths each year in the United States.

Energex's experimental treatment involves exposing a very small amount of an

infected subjects blood (3-4%) to a very precise amount of ultra-violet

light in the C band (UVC), for a very precise amount of time, explained

Petrie, the developer of the technology and Director of Engineering

at Energex Systems. " During treatment, a percentage of any pathogen in the

blood that is exposed to the UVC energy is inactivated. After exposure, the

blood carrying the inactive pathogen is returned to the patient through the

same portal it was drawn from. The result, we believe, is a stimulation of

the immune system " , said Petrie. The process takes 20-30 minutes.

In the trial, non-responders to Interferon/Ribaviran are administered 3 PCR

tests before treatment, on days 1,8, and 15. The average of the tests is the

baseline that post-treatment tests are compared to. After the blood draw on

day 15, the 1st treatment is administered, followed by the 2nd treatment on

day 17. Prior to the 3rd treatment on day 20, the first post-treatment PCR

test is administered and the result is compared to the baseline. The 4th and

5th treatments are administered on days 25 and 30 respectively. On day 33

the 1st PCR test after the last treatment is administered and compared to

the baseline. Additional PCR tests are administered on days 57, 64 and 71

and the average of the tests is compared to the baseline. Preliminary

results at day 33, established viral load reductions of 56, 91 and 96

percent in the 1st three trial participants.

" When you consider that we are treating non-responders; the average viral

load reduction of the 1st three participants was in excess of 81% in just a

17-day period, and there have been no adverse events, I believe it goes a

long way in validating our belief that our Hemo-Modulator technology will

soon become the treatment of choice for Hepatitis C and other RNA type

viruses " said J. Fagan, President of Energex Systems. We are excited

about the potential that our technology has to manage this hard-to-treat

disease, to reduce the cost of care, and to provide a better quality of life

for the millions that suffer from it. We are committed to expending whatever

resources are necessary to see that this technology continues through the

research and approval processes, and that it is accepted by the medical

community as the treatment of choice for this potentially life threatening

disease " , said Fagan.

Energex Systems is dedicated to developing medical technologies and

therapies with an emphasis on the treatment of conditions unmet by present

day therapies and reducing the cost of care.

Source: Energex Systems, Inc.